CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 277 filers reported holding CRISPR THERAPEUTICS AG in Q2 2020. The put-call ratio across all filers is 1.18 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $67,000 | -65.5% | 600 | -50.0% | 0.00% | – |
| Q2 2021 | $194,000 | +32.9% | 1,200 | 0.0% | 0.00% | – |
| Q1 2021 | $146,000 | -85.6% | 1,200 | 0.0% | 0.00% | – |
| Q4 2020 | $1,011,000 | +405.5% | 1,200 | -50.0% | 0.00% | -100.0% |
| Q3 2020 | $200,000 | +13.6% | 2,400 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $176,000 | +245.1% | 2,400 | +100.0% | 0.00% | – |
| Q1 2020 | $51,000 | -30.1% | 1,200 | 0.0% | 0.00% | – |
| Q4 2019 | $73,000 | +942.9% | 1,200 | +627.3% | 0.00% | – |
| Q3 2019 | $7,000 | -87.7% | 165 | -86.2% | 0.00% | – |
| Q2 2019 | $57,000 | +32.6% | 1,200 | 0.0% | 0.00% | – |
| Q1 2019 | $43,000 | +26.5% | 1,200 | 0.0% | 0.00% | – |
| Q4 2018 | $34,000 | -35.8% | 1,200 | 0.0% | 0.00% | – |
| Q3 2018 | $53,000 | -25.4% | 1,200 | 0.0% | 0.00% | -100.0% |
| Q2 2018 | $71,000 | -9.0% | 1,200 | -29.4% | 0.00% | 0.0% |
| Q1 2018 | $78,000 | +387.5% | 1,700 | +142.9% | 0.00% | – |
| Q4 2017 | $16,000 | – | 700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $32,581,000 | 55.55% |
| NEA Management Company, LLC | 1,590,002 | $103,907,000 | 5.19% |
| ARK Investment Management | 8,237,122 | $538,296,000 | 3.75% |
| Nikko Asset Management Americas, Inc. | 4,262,736 | $277,078,000 | 3.54% |
| CLOUGH CAPITAL PARTNERS L P | 414,767 | $27,105,000 | 2.89% |
| Integral Health Asset Management, LLC | 220,000 | $14,377,000 | 2.79% |
| PLUSTICK MANAGEMENT LLC | 50,000 | $3,268,000 | 2.48% |
| HC Advisors, LLC | 53,944 | $3,525,000 | 2.43% |
| Green Alpha Advisors, LLC | 27,466 | $1,795,000 | 1.52% |
| EFG Asset Management (North America) Corp. | 84,356 | $5,516,000 | 1.28% |